Anjan Sen will lead the operations for India and countries of South Asia region to drive the mission of delivering impactful medicines and solutions for a healthier every day for every woman by leveraging our existing position in women’s health to become the global leader in this space.
“In India, there is a high unmet need for family planning and at the same time, as per WHO estimates, about 3.9 to 16.8% of couples experience challenges in having children. As a business strategy, we will listen to women to understand their healthcare needs and find solutions which are relevant to them”, said Anjan Sen, who will lead the operations for India and countries in south Asia region. He also added, “Our vision and mission are aligned to the Government of India’s commitment to ensure access, choice, and quality of family planning services by expanding the range and reach of contraceptive options. We will consistently make efforts to ensure availability and access to quality healthcare products for women.”
Diverse Portfolio will Drive Sustainable Growth
At launch, Organon’s portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 countries, with nearly 80% of its revenue generated outside the USA. Organon is well positioned for organic low-to-mid-single digit growth from its 2021 base of business.
Organon in India and neighboring markets will firmly stand on its women’s health, fertility and established brands portfolio which will benefit from renewed management focus and enhanced commercial activities.
- Women’s Health: Organon has a portfolio of contraceptive and fertility brands anchored by market exclusivity for ImplanonNxt (etonogestrel implant) that has long-term growth potential. In India Organon is having 16% market share in the contraception and fertility market. In the coming years, Organon will focus on scaling up its contraceptive implant ImplanonNxt thereby offering a choice of quality contraception to women in the region.
- Biosimilars: Organon will be in a strong position with its current portfolio through its long-standing alliance with Samsung.
- Established Brands: Organon’s Established Brands business consists of 49 products across a range of therapeutic areas, including respiratory, cardiovascular, dermatology and non-opioid pain. The company will look to capitalize on these well-known and recognizable brands in the region.
Organon’s R&D philosophy is to build a business around patient needs, with the goal of identifying and advancing healthcare options for women that enable them to live their best lives every day. “For too long, for too many common conditions, such as heavy, painful, and irregular menstrual bleeding, incontinence, menopause and many others, women have been told to accept and normalize these conditions as a part of life,” said Sandy Milligan, Head of Organon Research & Development. “Organon’s mission is to change this. We believe this approach will be very successful — the ability to identify diseases earlier, the ability to modify the course of diseases or healthcare conditions and to ultimately, improve the quality of life for women at all stages.”
The company’s extensive global capabilities in clinical development and patient safety, regulatory and medical affairs make it well-positioned to identify promising drugs, diagnostics and devices with the greatest potential to impact women’s health.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.